Final data from the phase 2/3 study of Pfizer’s novel oral “at home” COVID-19 treatment, Paxlovid, was so strong, the candidate could be well-positioned to knock molnupiravir — which is authorized in the UK although not yet in the U.S. — off its perch.
Source: Drug Industry Daily